secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001178670-25-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q4 product rev $451M (+30%); FY rev $1.65B (+33%); vutrisiran sNDA PDUFA Mar 23
--------------------------------------------------------------------------------

- Q4 2024 global net product revenues $451M (+30% vs Q4 2023); full year $1,646M (+33%).
- Q4 total revenues $593.2M; net loss $83.8M improved from $137.9M loss in Q4 2023.
- FDA accepted sNDA for vutrisiran in ATTR cardiomyopathy; PDUFA target date March 23, 2025.
- Non-GAAP net income of $8.0M in Q4 vs loss of $96.6M in prior year.
- Company reiterates 2025 product sales and profitability guidance; R&D Day Feb 25, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000020/0001178670-25-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000020/alny-20250213.htm
  HTML page:      https://secwatch.observer/filing/0001178670-25-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer